Compare Oklo Inc (OKLO) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oklo Inc vs Pfizer Inc — how do they compare? Oklo Inc trades at $35.18 (market cap $6.43B), while Pfizer Inc trades at $27.81 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 24.7× Oklo Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Oklo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oklo Inc for 31 Days and Pfizer Inc for 158 Days on average.
| OKLO | PFE | |
|---|---|---|
Market Cap | $6.43B | $158.56B |
Volume | 16,238,368 | 44,138,282 |
Sector | Utilities | Health |
52-Week High | $174.14 | $29.02 |
52-Week Low | $34.57 | $23.67 |
Typical Hold Time | 31 Days | 158 Days |
Enterprise Value | $3.97B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKLO trades at $36.82, down 4.49% with bearish technical signals. The company shows no revenue in 2025 and negative net income of -$105.66M, with profitability metrics deeply negative. Recent earnings have missed expectations in two of the last three quarters. However, analyst sentiment remains strong with 71% buy ratings and a $78.63 consensus price target, reflecting optimism about the nuclear energy opportunity.
The outlook balances high growth potential in the nuclear sector against significant execution risks. While the $10 trillion nuclear opportunity and partnerships with hyperscalers provide upside, OKLO faces challenges including negative cash flow from operations, substantial dilution from recent stock sales, and intense competition in the small modular reactor market.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
